RxDoctor Payments Data

Sherrie Keltner

Psychiatric/Mental Health · Morehead, KYNPI 1346723855

Payments from drug & device makers

$2,305in general payments, 2019–2025

Across 74 payments — averaging $31.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$384
  • Teva Pharmaceuticals USA, Inc.$303
  • AbbVie$295
  • Johnson & Johnson$288
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$239
  • Neurocrine Biosciences, Inc.$201
  • plus $595 from 9 others

What the payments were for

  • Food & beverage$2,27899%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,305 in reported general payments places this provider in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,655
Medicare patients
13
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$41,743
RexultiBrexpiprazole20$37,584
Quetiapine Fumarate62$1,462
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$915
Hydroxyzine Hcl19$735
Duloxetine Hcl28$716
Buspirone Hcl43$408
Benztropine Mesylate26$356
Risperidone29$344
Propranolol Hcl16$297
Sertraline Hcl59$212
Trazodone Hcl32$205
Doxepin Hcl12$201
Bupropion XlBupropion Hcl15$195
Prazosin Hcl16$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$295$41,74331 claims
Otsuka America Pharmaceutical, Inc.Rexulti$120$37,58420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Morehead

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →